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S U M M A R Y
Background: Hepatitis B virus (HBV) is a gradually evolving virus. The aim of this study was to
characterize the distribution pattern of HBV genotypes and subgenotypes and HBsAg subtypes in chronic
hepatitis B subjects from the Indian subcontinent. We also sought to investigate the genetic diversity of
HBV genotypes and its inﬂuence on the therapeutic response.
Methods: A total of 295 chronic hepatitis B subjects were studied. HBV genotypes and subgenotypes
were determined using the generated HBV reverse transcriptase (rt) sequences. HBsAg subtypes were
predicted using a newly developed automated program in Microsoft Visual Basic (VB6). Genetic diversity
was characterized by calculating the mean genetic distance (d), the number of synonymous substitutions
per synonymous site (dS), and the number of non-synonymous substitutions per non-synonymous site
(dN). The virological response was measured by HBV DNA levels.
Results: In southern India, the predominant HBV subgenotype/subtype was D2/ayw3 (79.1%). In eastern
India, C1/adr (28.2%) was found to be the predominant subgenotype/subtype, followed by A1/adw2
(25.4%). In the north-eastern region, C2/adr, D2/ayw3, and D5/ayw3 were predominant and were each
identiﬁed in 20.8% of subjects. In treatment-naı¨ve subjects, the d, dS, and dN of genotype D sequences
were higher compared to genotypes C and A. Additionally, the d, dS, and dN of HBV rt sequence were
higher in subjects who subsequently showed a virological response to nucleos(t)ide analogues as
compared to non-responders, irrespective of the genotypes tested (p = 0.014 to p < 0.0001).
Conclusions: We have described the distribution of HBV genotypes and subgenotypes and HBsAg
subtypes in three major regions of the Indian subcontinent. HBV genetic diversity may play a pivotal role
in the clinical outcome of chronic hepatitis B.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
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Hepatitis B virus (HBV) is a circular, partially double-stranded
DNA virus of the family Hepadnaviridae. HBV replicates through a
reverse-transcribed RNA intermediate, and the low ﬁdelity rates of
the reverse transcriptase enzyme lead to highly error-prone
nucleotide synthesis.1 Hepadnaviruses are known to have origi-
nated more than 19 million years ago, and the evolutionary rate of
HBV is estimated to be 7.72  104 substitutions/site/year.2,3* Corresponding author. Tel.: +91 416 2282772; fax: +91 416 2232035.
E-mail address: priyaabraham@cmcvellore.ac.in (P. Abraham).
1201-9712  2014 The Authors. Published by Elsevier Ltd on behalf of International So
http://dx.doi.org/10.1016/j.ijid.2013.12.007Together with the higher evolutionary rate, selection pressure
imprints a high viral genetic diversity.
HBV is classiﬁed into genotypes and subgenotypes with an
intergenotypic diversity of 8% and intragenotypic diversity of 4%,
respectively.4 Accordingly, eight major HBV genotypes (A–H), two
novel genotypes (I and J), and several subgenotypes are well
described.4–7 HBV strains are also categorized into nine major
hepatitis B surface antigen (HBsAg) subtypes based on their
antigenic determinants in the major hydrophilic region.8 Further
extensive investigations may lead to the recognition of yet
unidentiﬁed HBV variants. HBV genotypes are known to show a
geographical pattern in their distribution and have been used to
trace the migration of populations from geographically distant
regions.7,9 Moreover, HBV genotypes and HBsAg subtypes have
been reported to inﬂuence disease progression and treatment
response.10–13 Therefore, the molecular characterization of HBV
strains is important for disease monitoring and clinical outcomes.ciety for Infectious Diseases. Open access under CC BY-NC-ND license.
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distribution pattern of HBV genotypes and subgenotypes and
HBsAg subtypes in chronic hepatitis B subjects from the Indian
subcontinent. We also characterized the genetic diversity between
HBV genotypes and its inﬂuence on the subsequent therapeutic
response.
2. Materials and methods
2.1. Study subjects
A total of 295 subjects with chronic hepatitis B were enrolled in
this study. The study subjects comprised individuals attending
the liver clinic of a tertiary care hospital in South India. The
subjects were recruited between January 2007 and November
2011 and were part of our HBV antiviral resistance mutations
study.14,15
2.2. HBV polymerase/reverse transcriptase gene ampliﬁcation and
sequencing
The HBV polymerase gene covering the entire reverse
transcriptase (rt) region was ampliﬁed using Platinum Taq High
Fidelity (Invitrogen, Carlsbad, CA, USA). PCR and the bi-directional
sequencing reaction were performed as described previously.14
The nucleotide sequences generated in this study have been
deposited in the GenBank database under accession numbers
GU798963 to GU799059 and JQ514280 to JQ514554.
2.3. Determination of HBV genotypes
HBV genotypes were determined using the HBVseq program in
the Stanford database.
2.4. Determination of HBV subgenotypes
The study sequences were aligned with published sequences
representing all known HBV subgenotypes.4,16–19 Multiple se-
quence alignment was performed using the built-in ClustalW
integrated in MEGA4.20 HBV subgenotypes were determined by
phylogenetic analysis in MEGA4 using the neighbour-joining
method with a bootstrap test of 1000 replicates and maximum
composite likelihood algorithm.
2.5. Determination of HBsAg subtypes
An automated computer programme for HBsAg subtype
determination was developed in Microsoft Visual Basic (VB6).
The overlapping surface gene sequence of HBV rt (155–835
nucleotides) was translated to the corresponding surface gene
amino acids using the BioEdit tool. The HBsAg subtypes were then
determined by the subtype program that examines every
combination of amino acids at positions 122, 160, 127, 159, and
140 (in that order), as deduced by Purdy et al.8
2.6. HBV genetic diversity
An analysis of the number of base substitutions per site
between sequences (genetic distance (d)) was conducted using the
maximum composite likelihood method in MEGA4. The number of
synonymous substitutions per synonymous site (dS) and the
number of non-synonymous substitutions per non-synonymous
site (dN) were calculated using the Nei–Gojobori model with
Jukes–Cantor correction in MEGA4. The baseline analysis was
performed for a total 197 treatment-naive chronic hepatitis B
subjects.2.7. Statistical analysis
Categorical variables were compared using the Chi-square test.
The d, dS, and dN were compared using the Kruskal–Wallis test. A
p-value of <0.05 was considered statistically signiﬁcant. All
analyses were done using Stata 12 (StataCorp, College Station,
TX, USA).
3. Results
The study subjects came from four regions of the Indian
subcontinent: southern, western, eastern, and north-eastern.
Subjects from the states of Tamil Nadu, Kerala, Karnataka, and
Andhra Pradesh and one subject from the Maldives in the south-
west of India represented the southern Indian subcontinent
population (n = 92). Two subjects were from the western Indian
states of Maharashtra and Rajasthan. The subjects of eastern India
came from West Bengal, Bihar, Jharkhand, and Orissa states and
Bangladesh (n = 177). Subjects from the states of Assam, Manipur,
Meghalaya, Tripura, and Arunachal Pradesh and the adjacent
country of Bhutan represented the north-eastern region (n = 24).
3.1. HBV genotypes
Three major HBV genotypes – A, C, and D – were found in this
population. HBV genotype D (n = 175; 59.3%) was found to be the
predominant circulating genotype, followed by genotypes C
(n = 67; 22.7%) and A (n = 53; 18.0%).
3.1.1. Regional distribution of HBV genotypes
There existed distinct patterns of HBV genotype circulation in
the study populations of the three main regions.
Among the 92 subjects from the southern region, HBV genotype
D was the predominant genotype, circulating in 82 (89.1%)
subjects. Genotypes A and C were less prevalent and were
identiﬁed in six (6.5%) and four (4.4%) subjects, respectively
(p < 0.0001).
Among the 177 subjects from the eastern region, HBV genotype
D was predominant, identiﬁed in 79 (44.6%) subjects. The other
common genotypes C and A were identiﬁed in 52 (29.4%) and 46
(26%) subjects, respectively (p = 0.0004).
Among the 24 subjects from the north-eastern region, genotype
D was identiﬁed in 12 (50%) subjects, genotype C in 11 (45.8%)
subjects, and genotype A in one (4.2%) subject (p = 0.001).
Genotype D was identiﬁed in the two subjects from the western
region.
3.2. HBV subgenotypes
All HBV genotype A sequences were identiﬁed as subgenotype
A1 (Figure 1). Among the 67 genotype C sequences, 58 (86.6%)
clustered to the C1 subgenotype and six (8.9%) to C2 (Figure 2). The
subgenotypes could not be determined in three (4.5%) genotype C
subjects.
HBV genotype D study sequences clustered into subgenotypes
D1 (n = 20, 11.4%), D2 (n = 112, 64%), D3 (n = 15, 8.6%), and D5
(n = 27, 15.4%) (Figures 3 and 4). The subgenotype could not be
determined for one (0.6%) genotype D sequence.
3.2.1. Regional distribution of HBV subgenotypes
The frequency and distribution of HBV subgenotypes are shown
in Table 1. There existed a signiﬁcant difference between
subgenotypes and study population regions (p < 0.001). To some
extent, the subgenotypes of genotypes C and D differed in their
regional distribution. The frequency of subgenotype C1 was higher
in the eastern region (86.2%). Among six subgenotype C2, ﬁve
Figure 1. Phylogenetic determination of HBV subgenotypes of genotype A. Phylogenetic analysis of HBV surface gene nucleotide sequences (665 positions) was constructed in
MEGA4 using the neighbour-joining method with a bootstrap test of 1000 replicates and maximum composite likelihood model. GenBank reference sequences are shown by
HBV subgenotype, accession number, and country of origin. Study sequences are designated by study number. Woolly monkey HBV (WM HBV) was used as an out-group.
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the north-eastern region. Subgenotypes D1, D3, and D5 were
identiﬁed in 80%, 93.3%, and 74.1% of subjects from the eastern
region, respectively. HBV subgenotype D2 was found to be
predominant in the southern region (68.7%).
3.3. HBsAg subtypes
A schematic representation of the newly developed automated
program for HBsAg subtype determination is illustrated in Figure 5.
In the subjects studied, six HBsAg subtypes – adr, adw2, adw3,
ayw1, ayw2, and ayw3 – were found to be circulating in the Indian
subcontinent. HBsAg subtypes ayw3, adr, adw2, and ayw2 were the
most common subtypes and were identiﬁed in 134 (45.4%), 66
(22.4%), 52 (17.6%), and 36 (12.2%) of the study subjects,
respectively. HBsAg subtypes ayw1 and adw3 were identiﬁed in
one (0.3%) subject each. HBsAg subtypes could not be determined
for ﬁve (1.7%) treatment-experienced subjects, as they presented
with unusual amino acid substitutions at surface gene positions
that are crucial for subtype determination.
3.3.1. HBsAg subtypes and genotype/subgenotype association
There existed a signiﬁcant association between HBV genotypes
and subtypes (p < 0.0001). In the analysis performed, HBsAg
subtypes adw2 and adr were always found to co-exist with
genotypes A and C, respectively. Likewise, HBsAg subtypes ayw2and ayw3 always presented in genotype D subjects. HBsAg subtype
adw3 was identiﬁed in one subject carrying subgenotype D2.
HBsAg subtype ayw1 was detected in one subject with genotype A.
3.4. Regional distribution of HBV genotypes and subgenotypes and
HBsAg subtypes
3.4.1. HBV genotype A and HBsAg subtypes
In 53 subjects identiﬁed with HBV genotype A, 52 (98.1%)
speciﬁcally carried subtype adw2 and the remaining one (1.1%)
subject presented with an unusual ayw1 subtype that is more
common in South African countries. Among these subjects, 46
(86.8%) were from the eastern region, six (11.3%) from the southern
region, and one (1.9%) from the north-eastern region of the Indian
subcontinent.
3.4.2. HBV genotype C and HBsAg subtypes
HBV genotype C was always associated with subtype adr and
was identiﬁed in 52 (77.6%) subjects from the eastern region, 10
(14.9%) subjects from the north-eastern region, and four (6%)
subjects from the southern region. The subtype of one (1.5%)
genotype C subject could not be assigned.
3.4.3. HBV genotype D and HBsAg subtypes
One subject from the southern region was identiﬁed with
subtype adw3. Most of the subtype ayw2 associated with genotype
Figure 2. Phylogenetic determination of HBV subgenotypes of genotype C. Phylogenetic analysis of HBV surface gene nucleotide sequences (644 positions) was constructed in
MEGA4 using the neighbour-joining method with a bootstrap test of 1000 replicates and maximum composite likelihood model. GenBank reference sequences are shown by
HBV subgenotype, accession number, and country of origin. Three samples that did not cluster with any of the known subgenotypes are indicated with shaded circles. Study
sequences are designated by study number. Woolly monkey HBV (WM HBV) was used as an out-group.
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followed by three (8.3%) from the southern region, two (5.6%) from
the north-eastern region, and one (2.8%) from the western region.
Subtype ayw3 was spread throughout the study population and
was identiﬁed in 75 (55.9%) subjects in the south, 48 (35.8%) in the
east, 10 (7.5%) in the north-east, and one (0.7%) in western India.
The HBsAg subtype could not be determined for four genotype D
subjects.
The overall distribution pattern of HBV subgenotypes and
HBsAg subtypes identiﬁed in this study is shown in Figure 6. In
southern India, the predominant HBV subgenotype/subtype was
D2/ayw3 (79.1%). In eastern India, C1/adr (28.2%) was the
predominant subgenotype/subtype, followed by A1/adw2
(25.4%), D2/ayw3 (15.3%), D5/ayw3 (11.3%), D1/ayw2 (8.5%), and
D3/ayw2 (7.9%). In the north-eastern region, C2/adr, D2/ayw3, and
D5/ayw3 were predominant, each identiﬁed in 20.8% of subjects.
Two subjects from western India had subgenotype/subtype D1/
ayw2 and D2/ayw3, and one subject from the Maldives of south-
west India was identiﬁed with D2/ayw3.
3.5. HBV genetic diversity
In order to identify the genetic diversity of HBV genotypes, d, dS,
and dN were studied in 197 treatment-naive subjects. Thereexisted a signiﬁcant difference between the three major HBV
genotypes studied (p < 0.0001). The d, dS, and dN of genotype D
were higher as compared to genotypes C and A (Table 2).
Further, to determine whether there is a signiﬁcant association
between the baseline sequence and treatment response, baseline
samples of subjects who subsequently showed a response (n = 79)
and those who did not respond (n = 44) to nucleos(t)ide analogues
(lamivudine or adefovir or entecavir) were analysed. The d, dS, and
dN were higher in responders as compared to non-responders,
irrespective of the genotypes tested (p = 0.014 to p < 0.0001;
Table 3). Responders were subjects who subsequently showed a 1
log10 IU/ml of HBV DNA reduction with a median treatment
duration of 6 months, or undetectable HBV DNA (<82 IU/ml) after a
median treatment duration of 12 months. Non-responders were
subjects who subsequently showed a < 1 log10 IU/ml reduction in
HBV DNA after a median treatment duration of 6 months, or
continued to be positive for HBV DNA after a median treatment
duration of 12 months.
4. Discussion
Our study enrolled a total of 295 subjects with chronic hepatitis
B infection from 15 states within India and three adjacent
countries, i.e., Bangladesh, Bhutan, and the Maldives. Most of
Figure 3. Phylogenetic determination of HBV subgenotypes of genotype D. Phylogenetic analysis of HBV surface gene nucleotide sequences (655 positions) was constructed in
MEGA4 using the neighbour-joining method with a bootstrap test of 1000 replicates and maximum composite likelihood model. GenBank reference sequences are shown by
HBV subgenotype, accession number, and country of origin. Study sequences are designated by study number. One sample that clustered with D4 is indicated with a shaded
circle and requires further analysis. Woolly monkey HBV (WM HBV) was used as an out-group.
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eastern India, and the north-eastern region. Additionally, a few
subjects were from south-west India and western India.
4.1. HBV genotypes and subgenotypes and HBsAg subtypes
The most common genotypes identiﬁed in India are A, C, and D.
HBV genotypes A and D were shown to be predominant in northern
and southern India, and genotype C in eastern India.21–25
Previously, our laboratory has reported the prevailing circulation
of HBV genotype D, followed by genotypes A and C in chronic
hepatitis B subjects.23,24 The present study also showed a
preponderance of genotype D (59.1%), but the frequency of
genotype C (22.6%) exceeded that of genotype A (17.9%). This
may be due to the inclusion of more subjects from eastern India.
Thus we found distinct patterns of HBV genotype circulation in the
study populations of the three main regions. Our data also showedincreasing evidence of genotype C circulation in southern India,
suggesting transmission routes from other regions. The progres-
sion of chronic infection is unfavourable in HBV genotype A and D
infections.26–28 Advanced stages of liver disease, including
hepatocellular carcinoma, are more often seen in chronic infection
with genotypes C and D.29–31 Given the clinical importance of
genotypes A, C, and D and their predominant circulation in the
Indian subcontinent, the utmost standard of care is warranted.
In our study, all HBV genotype A samples were identiﬁed as
subgenotype A1. Most of the genotype C was identiﬁed as
subgenotype C1 (86.6%), with a few subgenotype C2 (8.9%).
Among the six subgenotype C2, ﬁve (83.3%) were found to be
circulating in the Arunachal Pradesh state of north-east India,
which is bordered by China to the north, where subgenotype C2 is
more prevalent. This clearly suggests the transmission route of
subgenotype C2 to India. The subgenotypes of three (4.5%)
genotype C sequences and one (0.6%) genotype D sequence could
Figure 4. Phylogenetic determination of HBV subgenotypes of genotype D. Phylogenetic analysis of HBV surface gene nucleotide sequences (642 positions) was conducted in
MEGA4 using the neighbour-joining method with a bootstrap test of 1000 replicates and maximum composite likelihood model. GenBank reference sequences are shown by
HBV subgenotype, accession number, and country of origin. Study sequences are designated by study number. Woolly monkey HBV (WM HBV) was used as an out-group.
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in the recent guidelines, further analysis is required to conﬁrm the
newer subgenotype circulation in the Indian subcontinent.7,19
We have developed a new program to determine HBsAg
subtypes. The program uses the algorithm determined by PurdyTable 1
Regional distribution pattern of HBV subgenotypes
HBV subgenotype Total Region
Southern
(n = 92), n (%)
A1 53 6 (11.3) 
C1 58 4 (6.9) 
C2 6 0 
Ca (unassigned) 3 0 
D1 20 2 (10) 
D2 112 77 (68.7) 
D3 15 1 (6.7) 
D5 27 2 (7.4) 
Da (unassigned) 1 0 
HBV, hepatitis B virus.
a Three HBV genotype C sequences and one genotype D sequence could not be assiget al.8 to identify the nine major HBsAg subtypes currently known.
This tool enables the determination of HBsAg subtypes automati-
cally and reduces the time and error rates of manual procedures.
Hence it should be a useful tool, especially in the clinical setting
and for epidemiological studies. The program was validated byWestern
(n = 2), n (%)
Eastern
(n = 115), n (%)
North-eastern
(n = 87), n (%)
0 46 (86.8) 1 (1.9)
0 50 (86.2) 4 (6.9)
0 1 (16.7) 5 (83.3)
0 1 (33.3) 2 (66.7)
1 (5) 16 (80) 1 (5)
1 (0.9) 29 (25.9) 5 (4.5)
0 14 (93.3) 0
0 20 (74.1) 5 (18.5)
0 0 1 (100)
ned to any known subgenotypes using the surface gene sequences.
Figure 5. Schematic representation of the HBsAg subtype prediction tool. In the sequence alignment editor (A), HBV surface gene sequences (155–835 nucleotides of HBV
genome) are translated to the corresponding amino acid sequences. The amino acid codons are then copied and pasted into the HBV subtyping program (B). This program
examines every combination of amino acids at positions 122, 160, 127, 159, and 140, and the resulting HBV subtypes are displayed in the analysis window (C). The generated
results are then added to the Excel data sheet (D).
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published HBsAg subtypes.14 In the previous study, the subtypes of
97 subjects were determined manually by positioning the HBV
surface gene amino acids using BioEdit. In the present study, the
deduced subtypes were re-analysed using the new subtyping
program, and all 97 subtypes showed concordance to those of the
previously determined HBsAg subtypes.
In our study, we identiﬁed six HBsAg subtypes to be circulating
in the Indian subcontinent. The presence of the majority of HBsAg
subtypes in this population indicates a diverse virus population. To
our knowledge this is the ﬁrst report to show the prevalence of
circulating HBsAg subtypes across three regions of the Indian
subcontinent. The subtypes could not be determined in ﬁve (1.7%)
treatment-experienced subjects, as they presented with unusual
amino acid substitutions at surface gene positions that are crucial
for subtype determination. One reason could be the selectionpressure of antiviral drugs, which would have enabled these
variants to occur. As showed by Purdy et al.8 we also noticed a
signiﬁcant association between genotypes and HBsAg subtypes
(p < 0.0001). Therefore, distribution patterns of HBsAg subtypes
were mostly similar to those of the closely related genotypes.
4.2. HBV genetic diversity
HBV genotypes have been shown to be associated with disease
progression and the therapeutic response to immunomodulatory
drugs, indicating that the genetic heterogeneity of viral genotypes
may play a role in the virus–host relationship. The d, dS, and dN
were higher in genotype D sequences when compared to
genotypes A and C. This ﬁnding has also been evidenced in two
other studies; De Maddalena et al.32 showed high genetic
heterogeneity in genotype D as measured by higher dN values
Figure 6. Regional distribution pattern of HBV subgenotypes and HBsAg subtypes in the Indian subcontinent subjects with chronic HBV. The subgenotype/subtype in two
subjects from western India (D1/ayw2 and D2/ayw3) and one subject from the Maldives, south-west India (D2/ayw3) are not shown (untyp = untypeable).
Table 2
Genetic diversity of HBV genotypes in treatment-naive subjects. The table shows the mean genetic distance (d), the number of synonymous substitutions per synonymous
site (dS), and the number of non-synonymous substitutions per non-synonymous site (dN) of HBV reverse transcriptase sequences in treatment-naive subjects (N = 197)a
Genotype A (n = 32) Genotype C (n = 40) Genotype D (n = 125) p-Value
d (102 substitutions/site) 1.262 (0.019) 1.640 (0.038) 2.213 (0.0156) 0.0001
dS (102 substitutions/site) 2.988 (0.055) 4.460 (0.119) 6.049 (0.046) 0.0001
dN (102 substitutions/site) 0.719 (0.129) 0.641 (0.016) 0.814 (0.006) 0.0001
HBV, hepatitis B virus.
a Values are the mean with the standard error in parenthesis.
Table 3
Genetic diversity of HBV genotypes in treatment-naive subjects and subsequent response to nucleos(t)ide analogues. The table shows the mean genetic distance (d), the
number of synonymous substitutions per synonymous site (dS), and the number of non-synonymous substitutions per non-synonymous site (dN) of baseline HBV reverse
transcriptase sequences in responders and non-responders to nucleos(t)ide analoguesa,b
Responders Non-responders p-Value
Genotype A (n = 15) (n = 8)
d (102 substitution/site) 2.24 (0.223) 0.943 (0.494) 0.0001
dS (102 substitution/site) 5.406 (0.565) 2.389 (0.174) 0.0001
dN (102 substitution/site) 1.277 (0.131) 0 (0) 0.0001
Genotype C (n = 14) (n = 9)
d (102 substitution/site) 3.273 (0.252) 1.728 (0.188) 0.0001
dS (102 substitution/site) 8.884 (0.632) 4.453 (0.575) 0.0001
dN (102 substitution/site) 1.455 (0.144) 0.819 (0.086) 0.014
Genotype D (n = 50) (n = 27)
d (102 substitution/site) 2.821 (0.040) 2.196 (0.073) 0.0001
dS (102 substitution/site) 6.718 (0.108) 5.941 (0.212) 0.0001
dN (102 substitution/site) 1.480 (0.225) 0.978 (0.350) 0.0001
HBV, hepatitis B virus.
a Values are the mean with the standard error in parenthesis.
b Nucleos(t)ide analogues: lamivudine, adefovir, or entecavir.
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numbers of amino acid substitutions in genotype D than genotype
A. In our analysis, the d and dS were higher in genotype C than
genotype A. However, the dN was higher in genotype A than
genotype C.
Intriguingly, on analysis of the baseline sequence and subse-
quent response to nucleos(t)ide analogues, the d, dS, and dN were
higher in responders as compared to non-responders, irrespective
of the genotypes tested. These results contradict the ﬁndings of
Chen et al.34 In their analysis, the d, dS, and dN were signiﬁcantly
higher in non-responders after 4 weeks of lamivudine treatment.
They suggested that the antiviral pressure could have led to the
selection of mutants, and hence the viral genetic diversity in non-
responders was higher than in lamivudine responders. Another
study comparing the evolution of viral quasi-species between
hepatitis B e antigen (HBeAg) seroconversion and non-serocon-
version showed higher viral genetic diversity among responders
than non-responders.35 Fukai et al.36 showed a higher number of
HBV rt substitutions in the lamivudine responders than in non-
responders. These earlier published ﬁndings corroborate the
ﬁndings of the present study.
The concept of intermediate antiviral pressure and selection of
mutants37,38 can be extended in terms of host immune pressure
and adaptive mutations to explain this ﬁnding. At low immune
pressure, the virus replication is active and undergoes only a few
adaptive mutations. When immune pressure is high, there is a
complete suppression or very low levels of viral replication and
therefore no chance of mutant selection. However, at intermediate
levels of immune response, the virus evolves strategies to
counteract the selection pressure and therefore higher numbers
of mutations are observed. This hypothesis has also been proposed
by Lim et al. and others.35,39 We speculate that the selection
pressure of the host immune response could have led to high viral
genetic diversity in responders, which is supported by our earlier
study in which responders showed a better anti-HBe response and
elevated serum aminotransferases at baseline.15,40
In summary, we have described the distribution of HBV
genotypes and subgenotypes and HBsAg subtypes in three major
regions of the Indian subcontinent. The newly developed automated
program for HBsAg subtype determination would be a useful tool for
epidemiological and clinical studies. We hypothesize that high viral
genetic diversity, elevated baseline serum aminotransferases, and
spontaneous anti-HBe seroconversion, suggesting a high immune
response, combined with the action of nucleos(t)ide analogues will
yield a better virological response.
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